Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study

treatment with bilastine plus montelukast over 4 weeks does not consistently produce further improvements in SARC symptoms and AQLQ beyond those provided by either agents alone. Thus, there is no benefit of using bilastine plus montelukast to provide relief of SARC symptoms in partially controlled, mild-to-moderate asthma patients